Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia

Peter Vaupel*, Jürgen Dunst, Andreas Engert, Joachim Fandrey, Petra Feyer, Mathias Freund, Wolfgang Jelkmann

*Korrespondierende/r Autor/-in für diese Arbeit
23 Zitate (Scopus)

Abstract

It is well recognized that anemia-induced tumor hypoxia is associated with a reduced sensitivity of tumors to radiation and some forms of chemotherapy. Thus, the correction of lower hemoglobin (Hb) concentrations with recombinant human erythropoietin (rHuEPO) can play an essential role by improving tumor oxygenation. Based on evidence from a number of trials, treatment with rHuEPO will effectively ameliorate anemia and improve quality of life. However, one of the most essential prerequisites for achieving this benefit is the use of rHuEPO in agreement with the evidence-based ASCO/ASH-guidelines recommending a target Hb concentration of 12 g/dl (7.44 mmol/l).

OriginalspracheEnglisch
ZeitschriftOnkologie
Jahrgang28
Ausgabenummer4
Seiten (von - bis)216-221
Seitenumfang6
ISSN0378-584X
DOIs
PublikationsstatusVeröffentlicht - 04.2005

Fingerprint

Untersuchen Sie die Forschungsthemen von „Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren